

**Editor**

Josef S Smolen

Associate Editors

Francis Berenbaum
Dimitrios Boumpas
Gerd Burmester
Mary Crow
Kimme Hyrich
Rik Lories
Iain McInnes
Thomas Pap
David Pisetsky
Désirée van der Heijde
Kazuhiko Yamamoto

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 3655 5889
E: ard@bmj.com
Twitter: @ARD_BMJ
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)

Disclaimer: The Editor of *ARD* has been granted editorial freedom and *ARD* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *ARD* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *ARD* does not imply endorsement. Neither *EULAR* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *ARD* (except for liability which cannot be legally excluded).

Copyright: © 2020 BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced in any form without permission.

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases, ISSN 0003-4967 (USPS 2152) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent named WN Shipping USA, 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to *Annals of the Rheumatic Diseases*, WN Shipping USA, 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.

Editorial

- 849** Hopefulness of 'Hope'
D S Pisetsky

Recommendation

- 851** EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2
R BM Landewé, P M Machado, F Kroon, H WJ Bijlsma, G R Burmester, L Carmona, B Combe, M Galli, L Gossec, A Iagnocco, J D Isaacs, X Mariette, I McInnes, U Mueller-Ladner, P Openshaw, J S Smolen, T A Stamm, D Wiek, H Schulze-Koops

Epidemiology

- 859** Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
M Gianfrancesco, K L Hyrich, S Al-Adely, L Carmona, M I Danila, L Gossec, Z Izadi, L Jacobsohn, P Katz, S Lawson-Tovey, E F Mateus, S Rush, G Schmajuk, J Simard, A Strangfeld, L Trupin, K D Wysham, S Bhana, W Costello, R Grainger, J S Hausmann, J W Liew, E Sirotych, P Sufka, Z S Wallace, J Yazdany, P M Machado, P C Robinson, On behalf of the COVID-19 Global Rheumatology Alliance

Rheumatoid arthritis

- 867** Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD
E Ulijn, N den Broeder, M Wientjes, N van Herwaarden, I Meek, L Tweehuysen, A van der Maas, B JF van den Bemt, A A den Broeder
- 874** Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab
I H Shafraan, F Alasti, J S Smolen, D Aletaha
- 883** Improving rheumatoid arthritis comparative effectiveness research through causal inference principles: systematic review using a target trial emulation framework
S S Zhao, H Lyu, D H Solomon, K Yoshida

- 891** Implication of the deacetylase sirtuin-1 on synovial angiogenesis and persistence of experimental arthritis
A Leblond, S Pezet, A Cauvet, C Casas, J Pires Da Silva, R Hervé, G Clavel, S Dumas, S Cohen-Kaminsky, N Bessis, L Semerano, C Lemaire, Y Allanore, J Avouac
- 901** Ultrasound erosions in the feet best predict progression to inflammatory arthritis in anti-CCP positive at-risk individuals without clinical synovitis
A Di Matteo, K Mankia, L Duquenne, E Cipolletta, R J Wakefield, L Garcia-Montoya, J L Nam, P Emery
- 908** Ultrasound Doppler and tenosynovial fluid analysis in tenosynovitis
F Aslam, B R England, A Cannella, V Sharp, L Kao, J Arnason, J Albayda, C Bakewell, S Sanghvi, R Fairchild, K D Torralba, A Evangelisto, P J DeMarco, N Bethina, E Y Kissin

Spondyloarthritis

- 914** Real-world evidence of TNF inhibition in axial spondyloarthritis: can we generalise the results from clinical trials?
G T Jones, L E Dean, E Pathan, R J Hollick, G J Macfarlane
- 920** Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction
R BM Landewé, D van der Heijde, M Dougados, X Baraliakos, F E Van den Bosch, K Gaffney, L Bauer, B Hoepken, O R Davies, N de Peyrecave, K Thomas, L Gensler

MORE CONTENTS ►

Member since 2008

JM00004

This journal is a member of and subscribes to the principles of the

Committee on Publication Ethics

<http://publicationethics.org/>

When you have finished with this please recycle it

This article has been chosen by the Editor to be of special interest or importance and is freely available online.

This article has been made freely available online under the BMJ Journals open access scheme. See <http://authors.bmj.com/open-access/>

- 929** High prevalence of spondyloarthritis-like MRI lesions in postpartum women: a prospective analysis in relation to maternal, child and birth characteristics



T Renson, A Depicker, A-S De Craemer, L Deroo, G Varkas, M de Hooge, P Caron, L Jans, N Herregods, I Dehaene, G Vandenberghe, K Roelens, F E Van den Bosch, D Elewaut

- 935** Central reader evaluation of MRI scans of the sacroiliac joints from the ASAS classification cohort: discrepancies with local readers and impact on the performance of the ASAS criteria

W P Maksymowycz, S J Pedersen, U Weber, X Baraliakos, P M Machado, I Eshed, M de Hooge, J Sieper, S Wichuk, M Rudwaleit, D van der Heijde, R B M Landewé, D Poddubnyy, M Ostergaard, R G W Lambert

Systemic lupus erythematosus

- 943** Remission in systemic lupus erythematosus: testing different definitions in a large multicentre cohort



F Saccon, M Zen, M Gatto, D P E Margiotta, A Afeltra, F Ceccarelli, F Conti, A Bortoluzzi, M Govoni, G Frontini, G Moroni, F Dall'Ara, A Tincani, V Signorini, M Mosca, A C Frigo, L Iaccarino, A Doria

Vasculitis

- 951** Targeting JAK/STAT pathway in Takayasu's arteritis

P Régnier, A Le Joncour, A Maciejewski-Duval, A-C Desbois, C Comarmond, M Rosenzweig, D Klatzmann, P Cacoub, D Saadoun

Autoinflammatory disorders

- 960** Blood-based test for diagnosis and functional subtyping of familial Mediterranean fever



H Van Gorp, L Huang, P Saavedra, M Vuylsteke, T Asaoka, G Prencipe, A Insalaco, B Ogunjimi, J Jeyaratnam, I Cataldo, P Jacques, K Vermaelen, M Dullaers, R Joos, V Sabato, A Stella, J Frenkel, F De Benedetti, J Dehoorne, F Haerynck, G Calamita, P Portincasa, M Lamkanfi

Paediatric rheumatology

- 969** Treat-to-target study for improved outcome in polyarticular juvenile idiopathic arthritis
- A Klein, K Minden, A Hospach, I Foeldvari, F Weller-Heinemann, R Trauzeddel, H-I Huppertz, G Horneff*

Osteoarthritis

- 975** BCP crystals promote chondrocyte hypertrophic differentiation in OA cartilage by sequestering Wnt3a

J Bertrand, T Kräfft, T Gronau, J Sherwood, F Rutsch, F Lioté, F Dell'Accio, C H Lohmann, M Bollmann, A Held, T Pap

Letters

- 986** Hope

K Sheth

- 986** Susceptibility and severity of COVID-19 in patients treated with bDMARDs and tsDMARDs: a population-based study

C Salvarani, G Bajocchi, P Mancuso, E Galli, F Muratore, L Boiardi, M Catanoso, N Pipitone, G Cassone, N Girolimetto, S Croci, L Cimino, F Gradellini, M Beltrami, V Di Lernia, G Dolci, M Massari, A M Marata, M Costantini, P Giorgi Rossi

- 988** Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies



C Sanchez-Piedra, C Diaz-Torne, J Manero, J M Pego-Reigosa, Í Rúa-Figueroa, M A Gonzalez-Gay, J Gomez-Reino, J M Alvaro-Gracia, On behalf of the BIOBADASER study group

Electronic pages

- e79** TARA study: a new perspective on tapering drugs in RA

D Mishra, A Chattopadhyay, S Jain, V Dhir

- e80** Response to: 'TARA Study: a new perspective on tapering drugs in RA' by Mishra *et al*

E van Mulligen, J M W Hazes, A E A M Weel, P H P de Jong

- e81** Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from STRASS study

H Marotte, M Rinaudo-Gaujous, C Petiet, B Fautrel, S Paul

- e82** Response to: 'Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from the STRASS study' by Marotte *et al*

M J l'Ami, C L Krieckaert, M T Nurmohamed, R F van Vollenhoven, T Rispen, M Boers, G J Wolbink

- e83** Interosseous tendon inflammation of rheumatoid arthritis: what's the real meaning?

Z Deng, H Liu, W Lu

- e84** Response to: 'Interosseous tendon inflammation of rheumatoid arthritis: what's the real meaning?' by Deng *et al*
K Mankia, M-A D'Agostino, J Murillo-González, A Grainger, P Emery
- e85** Comment on: 'Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteria' by Greco *et al*
J Knitza, L Cavagna, G Schett, J H W Distler
- e86** Response to: 'Comment on: 'Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteria' by Greco *et al*' by Knitza *et al*
A Tjärnlund, I E Lundberg
- e87** Antisynthetase antibodies in clinical laboratories: the importance of clinical correlation and indirect immunofluorescence. Response to: Comment on: 'Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteria' by Greco *et al* by Knitza *et al*
M Greco, M^a J García de Yébenes, I Alarcón, A M Brandy-García, Í Rúa-Figueroa, E Loza, L Carmona
- e88** Can IL-1 be used as a target for osteoarthritis?
C Cheng, J Tian, F Zhang
- e89** Response to: 'Can IL-1 be used as a target for osteoarthritis?' by Cheng *et al*
M Kloppenburg, M Levesque